Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $16.00.

A number of brokerages have recently commented on EOLS. Weiss Ratings lowered Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a report on Wednesday, March 4th. Finally, Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th.

Evolus Price Performance

EOLS opened at $6.70 on Wednesday. Evolus has a fifty-two week low of $3.86 and a fifty-two week high of $10.62. The business has a 50-day moving average of $5.56 and a 200-day moving average of $5.56. The company has a market capitalization of $441.26 million, a PE ratio of -10.00 and a beta of 1.34.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $73.14 million during the quarter, compared to the consensus estimate of $72.52 million. During the same period in the previous year, the business earned ($0.30) earnings per share. On average, equities research analysts expect that Evolus will post -0.38 earnings per share for the current fiscal year.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 116,720 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $570,760.80. Following the transaction, the insider owned 618,369 shares of the company’s stock, valued at approximately $3,023,824.41. This represents a 15.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $146,680.44. Following the transaction, the insider directly owned 430,542 shares in the company, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 163,504 shares of company stock worth $797,184. 5.00% of the stock is currently owned by insiders.

Institutional Trading of Evolus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC grew its holdings in Evolus by 1.6% in the 4th quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock valued at $38,707,000 after buying an additional 93,792 shares during the last quarter. Caligan Partners LP grew its holdings in Evolus by 23.8% in the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after buying an additional 796,973 shares during the last quarter. Vanguard Group Inc. grew its holdings in Evolus by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after buying an additional 110,693 shares during the last quarter. Braidwell LP acquired a new stake in Evolus in the 4th quarter valued at approximately $20,650,000. Finally, Soleus Capital Management L.P. grew its holdings in Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after buying an additional 1,039,842 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.